Group 1 - The fund may trigger termination conditions as per the "Fund Contract" if the net asset value falls below 200 million yuan by April 29, 2025 [1] - The fund has a long history of small scale, and if it does not meet the asset threshold by the specified date, it will enter liquidation procedures starting April 30, 2025 [1] - Investors holding fund shares until the completion of the liquidation process will be exempt from all redemption fees [1] Group 2 - The fund will suspend subscription, regular investment, and transfer-in activities starting April 8, 2025 [2] - If termination conditions are met, redemption will be suspended from April 29, 2025, at 15:00, and any redemption requests after this time will not be confirmed [2] - A liquidation team will be established to carry out the fund's asset liquidation process, and investors will be unable to perform any transactions once the liquidation process begins [2] Group 3 - The interpretation rights of this announcement belong to Huatai Securities (Shanghai) Asset Management Co., Ltd. [3]

Group 1 - The fund, Huatai Zijin CSI Pharmaceutical 50 Index Fund, may trigger contract termination if its net asset value falls below 200 million yuan by April 29, 2025, which is three years after the contract's effective date [9] - The fund has been operating with a small scale, and if the asset size condition is not met, it will enter liquidation procedures starting April 30, 2025 [9][10] - Investors holding shares until the liquidation will be exempt from redemption fees [9] Group 2 - The fund will suspend subscription, regular investment, and conversion services starting April 8, 2025, and will also suspend redemption services from April 29, 2025, at 15:00 [10] - Investors are advised to complete any redemption requests before the specified deadline to avoid unprocessed applications [10] - The fund management will establish a liquidation team to handle the fund's assets according to relevant laws and regulations if the termination condition is triggered [10]